HEAL Study
Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers.
Short Description
To assess the safety, tolerance, and pharmacokinetics of multiple dosages of 75mg oral GBR 12909 in cocaine experienced volunteers. Effects on WBC and ANC will be the primary hematology outcome measure.
Release Date
May 23, 2017

This is a human laboratory study that will assess the clinical pharmacology, safety and tolerance of 75mg oral doses of GBR 12909, which is 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride, in cocaine experienced volunteers. Particular interest is being given to the hematological safety data.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
Study Links
Study Documents
Case Report Form(s)
Deidentification Notes
Nulled Values
All Documents